Skip to main content
    G

    Globus Medical (GMED)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $70.51
    -1.63 (-2.26%)

    Market Cap: $9.57B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Globus Medical (GMED) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Globus Medical (GMED) to earn $4.98 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.11B. Of 14 analysts, 10 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 13 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.07, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 71% of the ratings.

    RatingAnalystsShare
    Strong Buy321.4%
    Buy750.0%
    Hold428.6%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    14

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 7.2% and revenue estimates rise 5.5%.

    Fiscal year ending Dec 31, 2026
    $4.98
    EPS consensus, revenue $3.11B
    Fiscal year ending Dec 31, 2027
    $5.34
    EPS consensus, revenue $3.28B
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$4.98$4.92 to $5.0515$3.11B$3.09B to $3.22B15
    Dec 31, 2027$5.34$5.14 to $5.5215$3.28B$3.22B to $3.42B15

    Quarterly Estimates

    The EPS consensus falls from $1.31 for the quarter ending Dec 31, 2026 to $1.19 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$1.31$1.21 to $1.3917$792.53M$748.43M to $823.73M17
    Mar 31, 2027$1.19$1.09 to $1.2810$768.48M$725.35M to $795.24M8

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 27 upward and 5 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2026130
    Fiscal year ending Dec 31, 2027121
    Quarter ending Mar 31, 202724

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.4% from $4.96.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$4.98$5.00$5.00$5.00$4.96+0.3%
    Fiscal year ending Dec 31, 2027$5.34$5.39$5.40$5.40$5.340.0%
    Quarter ending Mar 31, 2027$1.19$1.22$1.22$1.22$1.21-2.1%

    Frequently Asked Questions About GMED

    What is the GMED stock forecast?

    Consensus analyst estimates put Globus Medical's EPS at $4.98 for the fiscal year ending Dec 31, 2026, on revenue of $3.11B. The consensus rating from 14 analysts is Buy.

    How do analysts rate GMED stock?

    Of 14 analysts covering Globus Medical, 3 rate it Strong Buy, 7 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from GMED next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $4.98, with estimates from $4.92 to $5.05 from 15 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $5.34, with estimates from $5.14 to $5.52 from 15 analysts.

    What revenue do analysts expect from Globus Medical next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.11B, with estimates from $3.09B to $3.22B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.28B, with estimates from $3.22B to $3.42B.

    How many analysts cover GMED?

    14 analysts rate Globus Medical stock, and 15 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.